<sup>18</sup>F-Fluorocholine PET/CT Is More Sensitive Than <sup>11</sup>C-Methionine PET/CT for the Localization of Hyperfunctioning Parathyroid Tissue in Primary Hyperparathyroidism.
Where this comes from
- Record sourced from PubMed, PMID 34413141.
- Also identified by DOI 10.2967/jnumed.121.262395.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Preoperative molecular imaging is paramount to direct surgery in primary hyperparathyroidism (pHPT). We investigated the diagnostic performance of <sup>18</sup>F-fluorocholine (<sup>18</sup>F-FCH) PET/CT compared with <sup>11</sup>C-methionine (<sup>11</sup>C-MET) PET/CT for localization of hyperfunctioning parathyroid tissue in patients with pHPT and negative or inconclusive <sup>99m</sup>Tc-sestaMIBI (<sup>99m</sup>Tc-MIBI) SPECT findings. <b>Methods:</b> Fifty-eight patients with biochemical evidence of pHPT and negative or inconclusive <sup>99m</sup>Tc-MIBI SPECT findings were referred for presurgical detection and localization of hyperfunctioning parathyroid tissue by <sup>11</sup>C-MET and <sup>18</sup>F-FCH PET/CT. The PET/CT results were classified into 3 categories (positive, inconclusive, or negative) based on the nodular aspect of tracer uptake and the visualization of corresponding nodules on CT. The PET/CT results were correlated with the surgical and histopathologic findings, which were used as the gold standard. <b>Results:</b> Fifty-three patients were included for analysis. <sup>18</sup>F-FCH PET/CT was positive in 39 patients (74%), inconclusive in 5 (9%), and negative in 9 (17%), compared with 25 (47%), 12 (23%), and 16 (30%), respectively, for <sup>11</sup>C-MET PET/CT. <sup>18</sup>F-FCH localized 11 additional foci (6 positive and 5 inconclusive), compared with <sup>11</sup>C-MET. Twenty-six patients (sex ratio, 10/16 M/F) underwent surgery, with resection of 31 lesions (22 adenomas, 6 hyperplastic glands, and 3 carcinomas) and 1 normal gland. At follow-up, 21 patients (81%) were considered cured after surgery, whereas 3 patients (12%) had persistence of hypercalcemia. With inconclusive cases being considered negative, <sup>18</sup>F-FCH PET/CT correctly localized 26 lesions in 24 of 26 patients (92%), compared with 16 lesions in 15 of 26 patients (58%) localized by <sup>11</sup>C-MET PET/CT. Per-patient-based sensitivity and positive predictive value were 96% and 96%, respectively, for <sup>18</sup>F-FCH and 60% and 94%, respectively, for <sup>11</sup>C-MET (<i>P</i> < 0.0001). Per-lesion-based sensitivity and positive predictive value were 84% and 90%, respectively, for <sup>18</sup>F-FCH and 52% and 94%, respectively, for <sup>11</sup>C-MET (<i>P</i> < 0.0001). <b>Conclusion:</b> In the presence of biochemical evidence of pHPT with negative or inconclusive <sup>99m</sup>Tc-MIBI SPECT findings, <sup>18</sup>F-FCH PET/CT performs better than <sup>11</sup>C-MET PET/CT for the detection of pathologic parathyroid tissue, allowing localization of parathyroid adenoma or hyperplasia in 96% of patients.
Medical subject headings
- Hyperparathyroidism, Primary
- Positron Emission Tomography Computed Tomography